Volatile organic compounds in exhaled air as novel marker for disease activity in Crohn's disease: A metabolomic approach

Inflammatory Bowel Diseases

Volumn 21, Issue 8, 2015, Pages 1776-1785

  Bodelier, Alexander G L ^a,b   Smolinska, Agnieszka ^c,d   Baranska, Agnieszka ^c,d   Dallinga, Jan W ^c   Mujagic, Zlatan ^a   Vanhees, Kimberly ^c   Van Den Heuvel, Tim ^b   Masclee, Ad A M ^b   Jonkers, Daisy ^b   Pierik, Marie J ^b   Van Schooten, Frederik J ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

Author keywords

Breath test; IBD; Noninvasive marker

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; VOLATILE ORGANIC COMPOUND; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; BREATHING; CLINICAL EVALUATION; CONTROLLED STUDY; CROHN DISEASE; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; EXPIRED AIR; FECES ANALYSIS; FEMALE; FOLLOW UP; GAS CHROMATOGRAPHY; HARVEY BRADSHAW INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SENSITIVITY AND SPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY; ADOLESCENT; BREATH ANALYSIS; CASE CONTROL STUDY; METABOLISM; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; BREATH TESTS; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLOMICS; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VOLATILE ORGANIC COMPOUNDS; YOUNG ADULT;

EID: 84946903705     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000436     Document Type: Article

References (57)

1. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380:1590-1605.
2. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
3. Regueiro M, Kip KE, Schraut W, et al. Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis. 2011;17:118-126.
4. af Bjorkesten CG, Nieminen U, Turunen U, et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol. 2012;47:528-537.
5. Vermeire S. Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:2-10.
6. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest. 1982;12:351-359.
7. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712.
8. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57:1518-1523.
9. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
10. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803-813.
11. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169.
12. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
13. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999;45:362-366.
14. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
15. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis. 2010;4:144-152.
16. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103:2007-2014.
17. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368.
18. Dhaliwal A, Zeino Z, Tomkins C, et al. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol. 2015;6:14-19.
19. Van Berkel JJ, Dallinga JW, Moller GM, et al. A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med. 2010;104:557-563.
20. Verdam FJ, Dallinga JW, Driessen A, et al. Non-alcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaled breath. J Hepatol. 2013;58:543-548.
21. Dallinga JW, Robroeks CMHHT, van Berkel JJBN, et al. Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children. Clin Exp Allergy. 2010;40:68-76.
22. Sedghi S, Keshavarzian A, Klamut M, et al. Elevated breath ethane levels in active ulcerative colitis: evidence for excessive lipid peroxidation. Am J Gastroenterol. 1994;89:2217-2221.
23. Pelli MA, Trovarelli G, Capodicasa E, et al. Breath alkanes determination in ulcerative colitis and Crohn's disease. Dis Colon Rectum. 1999;42:71-76.
24. Altomare DF, Di Lena M, Porcelli F, et al. Exhaled volatile organic compounds identify patients with colorectal cancer. Br J Surg. 2013;100:144-150.
25. de Meij TG, Larbi IB, van der Schee MP, et al. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study. Int J Cancer. 2014;134:1132-1138.
26. Miekisch W, Schubert JK, Noeldge-Schomburg GF. Diagnostic potential of breath analysis-focus on volatile organic compounds. Clin Chim Acta. 2004;347:25-39.
27. Boots AW, van Berkel JJ, Dallinga JW, et al. The versatile use of exhaled volatile organic compounds in human health and disease. J Breath Res. 2012;6:027108.
28. Van Berkel JJBN, Dallinga JW, Moeller GM, et al. Development of accurate classification method based on the analysis of volatile organic compounds from human exhaled air. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;861:101-107.
29. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014;63:88-95.
30. Smolinska A, Klaassen EM, Dallinga JW, et al. Profiling of volatile organic compounds in exhaled breath as a strategy to find early predictive signatures of asthma in children. PLoS One. 2014;9:e95668.
31. Smolinska A, Hauschild AC, Fijten RRR, et al. Current breathomics - a review on data pre-processing techniques and machine learning in metabolomics breath analysis. J Breath Res. 2014;8:027105.
32. Walczak B. Wavelets in Chemistry. Amsterdam, the Netherlands: Elsevier Science; 2000.
33. Eilers PHC, Marx BD. Flexible smoothing using B-splines and penalized likelihood. Stat Sci. 1996;11:89-121.
34. Nielsen NPV, Carstensen JM, Smedsgaard J. Aligning of single and multiple wavelength chromatographic profiles for chemometric data analysis using correlation optimised warping. J Chromatogr A. 1998;805:17-35.
35. Dieterle F, Ross A, Schlotterbeck G, et al. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in H-1 NMR metabonomics. Anal Chem. 2006;78:4281-4290.
36. Breiman L. Random forests. Mach Learn. 2001;45:5-32.
37. Snee RD. Validation of regression models: methods and examples. Technometrics. 1977;19:415-428.
38. Geladi P, Isaksson H, Lindqvist L, et al. Principal component analysis of multivariate images. Chemometr Intell Lab. 1989;5:209-220.
39. Burgard DR, Kuznicki JT. Chemometrics: Chemical and Sensory Data. Boca Rota, FL; 2000.
40. Stolk RP, Rosmalen JGM, Postma DS, et al. Universal risk factors for multifactorial diseases - LifeLines: a three-generation population-based study. Eur J Epidemiol. 2008;23:67-74.
41. Baranska A, Tigchelaar E, Smolinska A, et al. Profile of volatile organic compounds in exhaled breath changes as a result of gluten-free diet. J Breath Res. 2013;7:037104.
42. Hardoon DR, Szedmak S, Shawe-Taylor J. Canonical correlation analysis: an overview with application to learning methods. Neural Comput. 2004;16:2639-2664.
43. Lechner A, Colvin HP, Ginzel C, et al. Headspace screening of fluid obtained from the gut during colonoscopy and breath analysis by proton transfer reaction-mass spectrometry: a novel approach in the diagnosis of gastro-intestinal diseases. Int J Mass Spectrom. 2005;243:151-154.
44. Patel N, Alkhouri N, Eng K, et al. Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther. 2014;40:498-507.
45. Arasaradnam RP, Covington JA, Harmston C, et al. Review article: next generation diagnostic modalities in gastroenterology - gas phase volatile compound biomarker detection. Aliment Pharmacol Ther. 2014;39:780-789.
46. Chen X, Xu F, Wang Y, et al. A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. Cancer. 2007;110:835-844.
47. Xu ZQ, Broza YY, Ionsecu R, et al. A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions. Br J Cancer. 2013;108:941-950.
48. Torres MI, Rios A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol. 2008;14:1972-1980.
49. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007;52:2015-2021.
50. Buszewski B, Kesy M, Ligor T, et al. Human exhaled air analytics: biomarkers of diseases. Biomed Chromatogr. 2007;21:553-566.
51. McGrath LT, Patrick R, Silke B. Breath isoprene in patients with heart failure. Eur J Heart Fail. 2001;3:423-427.
52. Fuchs D, Jamnig H, Heininger P, et al. Decline of exhaled isoprene in lung cancer patients correlates with immune activation. J Breath Res. 2012;6:027101.
53. Garner CE, Smith S, de Lacy Costello B, et al. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J. 2007;21:1675-1688.
54. Ahmed I, Greenwood R, Costello Bde L, et al. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS One. 2013;8:e58204.
55. Haick H, Broza YY, Mochalski P, et al. Assessment, origin, and implementation of breath volatile cancer markers. Chem Soc Rev. 2014;43:1423-1449.
56. Arasaradnam RP, Ouaret N, Thomas MG, et al. A novel tool for noninvasive diagnosis and tracking of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:999-1003.
57. Arasaradnam RP, McFarlane MJ, Ryan-Fisher C, et al. Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis. PLoS One. 2014;9:e108750.